An analysis of deep vein thrombosis in burn patients (part II): A randomized and controlled study of thrombo-prophylaxis with low molecular weight heparin

被引:16
|
作者
Ahuja, Rajeev B. [1 ,3 ]
Bansal, Priya [1 ,3 ]
Pradhan, Gaurav S. [2 ,3 ]
Subberwal, Manju [3 ,4 ]
机构
[1] Dept Burns & Plast Surg, New Delhi 110 Q2002, India
[2] Lok Nayak Hosp, Dept Radiol, New Delhi 110002, India
[3] Associated Maulana Azad Med Coll, New Delhi 110002, India
[4] GB Pant Hosp, Dept Biochem, New Delhi 110002, India
关键词
Deep vein thrombosis; DVT in burns; DVT prophylaxis; THERMALLY INJURED PATIENTS; VENOUS THROMBOEMBOLISM; RISK-FACTORS; COMPLICATIONS; PREVENTION; GUIDELINES; ENOXAPARIN; SURGERY; CENTERS; COST;
D O I
10.1016/j.burns.2016.08.007
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Introduction: Morbidity and mortality from venous thrombo-embolism (VTE) remains a significant problem for trauma and medical patients and there are established guidelines for prophylaxis in these patients. However, the efficacy and safety of VTE prophylaxis in thermally injured patients continue to be elusive as it has never been studied in a prospective, randomized fashion. Selective use of VTE prophylaxis, for high risk patients, is practiced by some burn units even if objective evidence is lacking for majority of risk factors enunciated in burn patients. Differing demographics and wound management techniques are other confounding factors mandating more prospective studies to evaluate the need and role of chemoprophylaxis for deep vein thrombosis (DVT) prevention in burn patients. Ours is the first prospective, randomized, controlled study which seeks to identify risk factors for DVT in our patients, and evaluate the role of routine chemoprophylaxis and its complications. Methods: The study design (sample size, inclusion/exclusion criteria, randomization, methodology and statistical methods) is detailed in part-1 of this two part manuscript. Results: Doppler ultrasound (DUS) identified DVT in four out of 50 patients (8% incidence) forming the control group. DVT was not detected in any of the patients on prophylaxis (0% incidence). This difference was found to be statistically significant (p value-0.021). Patients with DVT had significantly higher %TB SA, prolonged immobility and a longer duration of stay as compared to patients without DVT in the control group. Only one patient on enoxaparin prophylaxis developed mild epistaxis which resolved spontaneously. Fifteen patients died during the study out of which two had DVT but none showed autopsy evidence of pulmonary embolism. Conclusion: With a moderate risk of developing DVT (8%) and a complication rate of only 2% with chemoprophylaxis, we feel that routine prophylaxis has the potential to decrease the incidence of VTE, without associated complications, in the moderate to high risk category. (C) 2016 Elsevier Ltd and ISBI. All rights reserved.
引用
收藏
页码:1693 / 1698
页数:6
相关论文
共 50 条
  • [1] RANDOMIZED CONTROLLED-STUDY OF HEPARIN AND LOW-MOLECULAR-WEIGHT HEPARIN FOR PREVENTION OF DEEP-VEIN THROMBOSIS IN MEDICAL PATIENTS
    HARENBERG, J
    KALLENBACH, B
    MARTIN, U
    DEMPFLE, CE
    ZIMMERMANN, R
    KUBLER, W
    HEENE, DL
    [J]. THROMBOSIS RESEARCH, 1990, 59 (03) : 639 - 650
  • [2] DEEP-VEIN THROMBOSIS PROPHYLAXIS AND LOW-MOLECULAR-WEIGHT HEPARIN
    VALLANO, A
    ARNAU, JM
    VALLES, JA
    [J]. MEDICINA CLINICA, 1991, 97 (07): : 272 - 275
  • [3] Low molecular weight heparin (LMWH) for primary thrombo-prophylaxis in patients with solid malignancies - systematic review and meta-analysis
    Ben-Aharon, Irit
    Stemmer, Salomon M.
    Leibovici, Leonard
    Shpilberg, Ofer
    Sulkes, Aaron
    Gafter-Gvili, Anat
    [J]. ACTA ONCOLOGICA, 2014, 53 (09) : 1230 - 1237
  • [4] Low molecular weight heparin for deep vein thrombosis in glioma patients
    Schmidt, F
    Faul, C
    Dichgans, J
    Weller, M
    [J]. JOURNAL OF NEUROLOGY, 2002, 249 (10) : 1409 - 1412
  • [5] Low molecular weight heparin for deep vein thrombosis in glioma patients
    Friederike Schmidt
    Christoph Faul
    Johannes Dichgans
    Michael Weller
    [J]. Journal of Neurology, 2002, 249 : 1409 - 1412
  • [6] Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
    Lopaciuk, S
    Bielska-Falda, H
    Noszczyk, W
    Bielawiec, M
    Witkiewicz, W
    Filipecki, S
    Michalak, J
    Ciesielski, L
    Mackiewicz, Z
    Czestochowska, E
    Zawilska, K
    Cencora, A
    Tomkowski, WZ
    Hajduk, B
    Kloczko, J
    Mazgajska, K
    Jaromin, J
    Chmielecki, Z
    Niedziela, P
    Czekalski, P
    Molski, S
    Kwiatkowski, C
    Psuja, P
    Lewandowski, K
    Muszynski, R
    Kicinska, M
    [J]. THROMBOSIS AND HAEMOSTASIS, 1999, 81 (01) : 26 - 31
  • [7] Low molecular weight heparin versus acenocoumarol in the secondary prophylaxis of deep vein thrombosis
    Lopaciuk, S
    [J]. THROMBOSIS AND HAEMOSTASIS, 1997, : HI4 - HI4
  • [8] Randomized, controlled trial of low molecular weight heparin vs. no deep vein thrombosis prophylaxis for major colon and rectal surgery in Asian patients
    Ho, YH
    Seow-Choen, F
    Leong, A
    Eu, KW
    Nyam, D
    Teoh, MK
    [J]. DISEASES OF THE COLON & RECTUM, 1999, 42 (02) : 196 - 202
  • [9] Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study
    Lavau-Denes, Sandrine
    Lacroix, P.
    Maubon, A.
    Preux, P. M.
    Genet, D.
    Venat-Bouvet, L.
    Labourey, J. L.
    Martin, J.
    Slaouti, P.
    Tubiana-Mathieu, N.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (01) : 65 - 73
  • [10] Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study
    Sandrine Lavau-Denes
    P. Lacroix
    A. Maubon
    P. M. Preux
    D. Genet
    L. Vénat-Bouvet
    J. L. Labourey
    J. Martin
    P. Slaouti
    N. Tubiana-Mathieu
    [J]. Cancer Chemotherapy and Pharmacology, 2013, 72 : 65 - 73